Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago.
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN's (QGEN) progress in test menu expansion, prospects in molecular diagnostics and strong solvency bode well.
Qiagen (QGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
QIAGEN (QGEN) announces a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance the identification of human remains of Indigenous people and African Americans.
QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.
QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.
QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.
QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.